{"organizations": [], "uuid": "45149d936f1ec48b059bb7499a001d3554c382c6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/legal", "section_title": "Legal News | Reuters", "url": "https://www.reuters.com/article/ip-patent-endo/ftc-judge-rejects-agencys-challenge-to-endo-impax-pay-for-delay-deal-idUSL2N1SS1QB", "country": "US", "domain_rank": 408, "title": "FTC judge rejects agency's challenge to Endo-Impax pay for delay deal", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.017, "site_type": "news", "published": "2018-05-22T05:30:00.000+03:00", "replies_count": 0, "uuid": "45149d936f1ec48b059bb7499a001d3554c382c6"}, "author": "Jan Wolfe", "url": "https://www.reuters.com/article/ip-patent-endo/ftc-judge-rejects-agencys-challenge-to-endo-impax-pay-for-delay-deal-idUSL2N1SS1QB", "ord_in_thread": 0, "title": "FTC judge rejects agency's challenge to Endo-Impax pay for delay deal", "locations": [], "entities": {"persons": [{"name": "d. michael chappell", "sentiment": "none"}], "locations": [], "organizations": [{"name": "ftc", "sentiment": "negative"}, {"name": "endo international plc", "sentiment": "none"}, {"name": "u.s. federal trade commission", "sentiment": "none"}, {"name": "impax laboratories llc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "A patent litigation settlement that delayed by three years the introduction of a generic painkiller did not violate consumer protection laws, a U.S. Federal Trade Commission judge ruled in a decision made public on Friday.\nFTC chief administrative law judge D. Michael Chappell dismissed a complaint filed by the agency against generic drug maker Impax Laboratories LLC over its 2010 deal to postpone a generic version of Endo International Plcâ€™s Opana ER until 2013 was anticompetitive.\nTo read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2KLLGqT\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/", "http://bit.ly/2KLLGqT"], "published": "2018-05-22T05:30:00.000+03:00", "crawled": "2018-05-22T02:39:19.000+03:00", "highlightTitle": ""}